1. Synthesis and Antiviral Evaluation of (1,4-Disubstituted-1,2,3-triazol)-(E)-2-Methyl-but-2-enyl Nucleoside Phosphonate Prodrugs. Abuduaini, T., V. Roy, J. Marlet, C. Gaudy-Graffin, D. Brand, C. Baronti, F. Touret, B. Coutard, T.R. McBrayer, R.F. Schinazi, and L.A. Agrofoglio. Molecules, 2021. 26(5): 1493. PMID[33803417]. PMCID[PMC7967160].
[PubMed]. HIV_03_2021.
2. Malva sylvestris Derivatives as Inhibitors of HIV-1 BaL Infection. Benso, B., P.L. Rosalen, S. Pasetto, M.C.S. Marquezin, V. Freitas-Blanco, and R.M. Murata. Natural Product Research, 2021. 35(6): p. 1064-1069. PMID[31429300].PMCID[PMC7031020].
[PubMed]. HIV_03_2021.
3. Himalayan Bioactive Molecules as Potential Entry Inhibitors for the Human Immunodeficiency Virus. Bhardwaj, V.K., R. Purohit, and S. Kumar. Food Chemistry, 2021. 347: 128932. PMID[33465692].
[PubMed]. HIV_03_2021.
4. Covalent Inhibition of Wild-type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead. Ippolito, J.A., H.C. Niu, N. Bertoletti, Z.J. Carter, S.Y. Jin, K.A. Spasov, J.A. Cisneros, M. Valhondo, K.J. Cutrona, K.S. Anderson, and W.L. Jorgensen. ACSMedicinal Chemistry Letters, 2021. 12(2): p. 249-255. PMID[33603971]. PMCID[PMC7883463].
[PubMed]. HIV_03_2021.
5. Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket. Part 2: Discovery of Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs with High Fsp3 Values and Favorable Drug-Like Properties. Jiang, X., B. Huang, F.A. Olotu, J. Li, D. Kang, Z. Wang, E. de Clercq, M.E.S. Soliman, C. Pannecouque, X. Liu, and P. Zhan. European Journal of Medicinal Chemistry, 2021. 213: 113051. PMID[33279288].
[PubMed]. HIV_03_2021.
6. Synthesis and Anticancer Properties of Functionalized 1,6-Naphthyridines. Lavanya, M., C. Lin, J.C. Mao, D. Thirumalai, S.R. Aabaka, X.J. Yang, J.H. Mao, Z.Y. Huang, and J.Z. Zhao. Topics in Current Chemistry, 2021. 379(2): 13. PMID[33624162].
[PubMed]. HIV_03_2021.
7. The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency. Mori, L., K. Jenike, Y.H.J. Yeh, B. Lacombe, C. Li, A.J. Getzler, S. Mediouni, M.E. Cameron, M.E. Pipkin, Y.C. Ho, B.C. Ramirez, and S.T. Valente. Journal of Virology, 2021. 95(4). PMID[33239456]. PMCID[PMC7851559].
[PubMed]. HIV_03_2021.
8. Rational Design of a Novel Small-molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. Pu, J., Y. Dai, Q. Wang, L. Lu, J.Q. Zhang, W. Xu, L. Xie, S.Q. Wang, F. Yu, X.Y. He, and S.B. Jiang. Frontiers in Pharmacology, 2021. 11: 613361. PMID[33569006]. PMCID[PMC7868322].
[PubMed]. HIV_03_2021.
9. Design, Synthesis and Characterization of HIV-1 CA-targeting Small Molecules: Conformational Restriction of PF74. Sahani, R.L., R. Diana-Rivero, S.K.V. Vernekar, L. Wang, H. Du, H. Zhang, A.E. Castaner, M.C. Casey, K.A. Kirby, P.R. Tedbury, J. Xie, S.G. Sarafianos, and Z. Wang. Viruses, 2021. 13(3): 479. PMID[33804121]. PMCID[PMC8000227].
[PubMed]. HIV_03_2021.
10. Identification of Novel Potent HIV-1 Inhibitors by Exploiting the Tolerant Regions of the NNRTIs Binding Pocket. Sun, Y., D. Kang, F. Da, T. Zhang, P. Li, B. Zhang, E. De Clercq, C. Pannecouque, P. Zhan, and X. Liu. European Journal of Medicinal Chemistry, 2021. 214: 113204. PMID[33567378].
[PubMed]. HIV_03_2021.
11. Design and Exploration of C-3 Benzoic acid Bioisosteres and Alkyl Replacements in the Context of GSK3532795 (BMS-955176) That Exhibit Broad Spectrum HIV-1 Maturation Inhibition. Swidorski, J.J., S. Jenkins, U. Hanumegowda, D.D. Parker, B.R. Beno, T. Protack, A. Ng, A. Gupta, Y. Shanmugam, I.B. Dicker, M. Krystal, N.A. Meanwell, and A. Regueiro-Ren. Bioorganic & Medicinal Chemistry Letters, 2021. 36: 127823. PMID[33508465].
[PubMed]. HIV_03_2021.
12. Synthesis, Molecular Docking and Molecular Dynamics Simulation of 2-Thioxothiazolidin-4-one Derivatives against gp41. Tamiz, N., T. Mostashari-Rad, A. Najafipour, S. Claes, D. Schols, and A. Fassihi. Current HIV Research, 2021. 19(1): p. 47-60. PMID[32885756].
[PubMed]. HIV_03_2021.
13. Novel PF74-like Small Molecules Targeting the HIV-1 Capsid Protein: Balance of Potency and Metabolic Stability. Wang, L., M.C. Casey, S.K.V. Vernekar, R.L. Sahani, K.A. Kirby, H. Du, H. Zhang, P.R. Tedbury, J. Xie, S.G. Sarafianos, and Z. Wang. Acta Pharmaceutica Sinica B, 2021. 11(3): p. 810-822. PMID[33777683]. PMCID[PMC7982424].
[PubMed]. HIV_03_2021.
14. Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. Wang, X., M. Cao, Y. Wu, W. Xu, Q. Wang, T. Ying, L. Lu, and S. Jiang. Molecules, 2021. 26(7):1964. PMID[33807292]. PMCID[PMC8036483].
[PubMed]. HIV_03_2021.
15. In vitro anti-HIV-1 Activity of the Recombinant HIV-1 TAT Protein Along with Tenofovir Drug. Yadavar-Nikravesh, M.S., A. Milani, R. Vahabpour, M. Khoobi, H. Bakhshandeh, and A. Bolhassani. Current HIV Research, 2021. 19(2): p. 138-146. PMID[33045968].
[PubMed]. HIV_03_2021.
16. Total Synthesis and Biological Evaluation of the Potent HIV Latency-reversing Agent Ansellone A and Its Analogues. Yanagihara, M., K. Murai, N. Kishimoto, T. Abe, S. Misumi, and M. Arisawa. Org Lett, 2021. 23(5): p. 1720-1725. PMID[33570413].
[PubMed]. HIV_03_2021.
Patent Citations
17. Synthesis of 4'-Ethynyl-2'-deoxyadenosine Derivatives as anti-HIV Agents. De La Rosa, M.A., J. Miller, L.S. Suwandi, D. Temelkoff, and E.J. Velthuisen. Patent. 2021. 2020-IB58046 2021038509: 111pp.
[Patent]. HIV_03_2021.